NCT06475781 - Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD | Biotech Hunter

Enrollment

126

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

August 31, 2028

Conditions

Group 3 Pulmonary Hypertension

Interventions

DRUG

Mirivadelgat

Selective aldehyde dehydrogenase 2 (ALDH2) activator

DRUG

placebo

Trial Locations (9)

RECRUITING

MacKay Memorial Hospital, Taipei

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Kaohsiung Veterans General Hospital, Kaohsiung City

RECRUITING

Hualien Tzu Chi Hospital, Hualien City

RECRUITING

Taipei Veterans General Hospital, Taipei

RECRUITING

National Taiwan University Hospital, Taipei

RECRUITING

Taichung Veterans General Hospital, Taichung

RECRUITING

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

RECRUITING

Chang Gung Memorial Hospital - Linkou Branch, Taoyuan